ARRS Opportunities and Obligations in Imaging Patients with Alzheimer’s Disease 2025
- Free Shipping on orders over 45$
- In stock, ready to ship
- Inventory on the way
ARRS Opportunities and Obligations in Imaging Patients with Alzheimer’s Disease 2025
Date of Original Release: Aug 2025
Anti-amyloid targeting disease-modifying therapies for Alzheimer’s disease present an exciting opportunity to dramatically impact the lives of patients with Alzheimer’s dementia. The imaging impact is already formidable, with a significant rise in MRI volume. Amyloid PET volumes have also skyrocketed following a positive reimbursement decision for patient selection and treatment surveillance.
Learning Outcomes and Modules
After completing this course, the learner should be able to:
- Identify the challenges and opportunities of AD in the era of DMT.
- Discuss the benefits and risks of amyloid targeting therapies.
- Discuss clinical implications of ARIA grading and multidisciplinary communication.
- Recognize the role of molecular imaging in the dementia imaging pathway.
Speakers and Lectures
- Multimodal Dementia Imaging with Emphasis on Alzheimer’s Disease and ARIA Cases—Suzie Bash
- Enterprise Workflow Optimization for Alzheimer’s Screening and ARIA Surveillance—Lawrence Tanenbaum
- Radiology Perspective: Multidisciplinary Approach to Challenging Cases—Tammie Benzinger
- Orders under 45$ will have a shipping charge of a flat rate of 15$.
-Orders over 45$ will have Free Shipping.